Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Abbott Laboratories

This Is What Whales Are Betting On Abbott Laboratories

Someone with a lot of money to spend has taken a bullish stance on Abbott Laboratories (NYSE:ABT). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

5 Stocks With the Most Long-Term Growth Potential

While high inflation and GDP decline for two consecutive quarters are raising recession fears, better-than-expected corporate profits and the possibility of a less aggressive rate hike have been restoring investor confidence. Regardless of the uncertainties surrounding the economy and the market, investing in Abbott Laboratories (ABT), Coca-Cola Consolidated (COKE), DLH…

StockNews.com

The Best Stock to Buy for Long-Term Growth

Healthcare company Abbott Labs (ABT) has demonstrated solid growth over the past years. Moreover, the company announced its plans to restart its baby formula business in Michigan. And considering its fundamental strength, we think the stock might be an ideal investment for long-term growth. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Abbott Labs A "Strong Buy" After Earnings?

Leading healthcare company Abbott Laboratories (ABT) reported strong second-quarter results. And given the company is well-positioned to capitalize on its diverse business and recent FDA approvals, is it wise to buy the stock now? Let’s find out.

StockNews.com

Abbott reports strong earnings despite infant formula crisis

Abbott Laboratories reported strong earnings Wednesday, despite spending recent months responding to criticism over problems that led to the shutdown of one of its infant formula-producing plants.

Chicago Tribune

Abbott Posts Beastly Covid Testing Growth — But It's Not Sustainable

Abbott Laboratories can credit its Covid testing efforts for its second-quarter beat, an analyst said Wednesday. But ABT stock toppled.

Investors Business Daily

U.S. Stock Futures Edge Higher; Tesla Earnings In Focus

Pre-open movers

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Is Abbott Stock a Buy at $105 as Production in Troubled Plant Resumes?

Leading healthcare company Abbott Laboratories (ABT) reported robust first-quarter results. And the company is well-positioned to benefit from its diversified business. Moreover, as ABT is resuming infant formula production at its Michigan facility, is the stock a good buy at the current price level? Read more to find out….

StockNews.com

This Biotech Stock Looks Like a Prime Growth Play

Diversified healthcare company Abbott (ABT) has demonstrated significant innovations across its segments, and given its dominant market position, the company’s prospects look bright. The stock could be a solid choice as it is well-positioned to survive short-term market fluctuations. Let’s discuss this in detail….

StockNews.com

What 6 Analyst Ratings Have To Say About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings within the last quarter:

Benzinga

Here's How Much $1000 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 7.3% on an annualized basis producing an average annual return of 17.14%. Currently, Abbott Laboratories has a market capitalization of $187.96 billion.

Benzinga

This Top-Rated Healthcare Stock Is Trading at a 25% Discount

Medical device company Abbott Laboratories (ABT) reported impressive first-quarter results and affirmed its strong performance guidance for fiscal 2022. Furthermore, the company is well-positioned to benefit from its diversified business. However, amid the heightened market volatility, the stock is trading 25.5% below its 52-week high. So, the current dip in…

StockNews.com

FDA Probes Another Infant Death Given Abbott Formula, Less Than Month After Troubled Plant Reopens

Problems for Abbott Laboratories' (NYSE: ABT) Sturgis plant in Michigan for baby formula powder refuse to subside. The FDA was recently notified of another infant's death who was given formula made at Abbott's Sturgis facility.

Benzinga

FDA investigates death of another infant given Abbott formula

U.S. Food and Drug Administration officials are investigating the death of another infant who was given formula made by Abbott Laboratories.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - US

Key US baby formula plant closes again as ‘torrential storms’ cause flooding

Production halt at Abbott Laboratories in Michigan will probably extend shortages for ‘a few weeks’

Benzinga

More Trouble For Baby Formula Production As Thunderstorms, Flood, Hit Abbott's Troubled Michigan Plant

Just a few weeks after reopening its baby formula Sturgis, Michigan plant, Abbott Laboratories (NYSE:ABT) said it paused EleCare specialty baby formula production after recent thunderstorms flooded part of the facility. The company has informed the FDA and will conduct comprehensive testing with an independent third party to ensure the plant is safe to…

StockNews.com

5 Hard-Hit Large-Cap Stocks Ready to Rebound

The market turmoil this year, due to the sky-high inflation and the Fed’s hawkish tilt, has led several fundamentally solid large-cap stocks to trade below their intrinsic values. However, we believe quality large-cap stocks Broadcom (AVGO), Abbott (ABT), IQVIA (IQV), Agilent (A), and QUALCOMM (QCOM), which have declined significantly in…

Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,900 Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.54% on an annualized basis producing an average annual return of 14.5%. Currently, Abbott Laboratories has a market capitalization of $201.08 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyzing Abbott Laboratories's Short Interest

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 5.48% since its last report. The company recently reported that it has 13.46 million shares sold short, which is 0.77% of all regular shares that are available for trading.

StockNews.com

Abbott Laboratories vs. Edwards Lifesciences: Which Medical Device Stock is a Better Investment?

The growing prevalence of chronic diseases, an increasing elderly population, and rapid adoption of advanced medical technologies are driving the growth of the medical device industry. The industry is expected to witness solid growth over the long term, to the benefit of the stocks of medical device companies Abbott (ABT)…

Benzinga

5 Analysts Have This to Say About Abbott Laboratories

Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Reuters

Abbott reopens baby formula plant in Michigan

Abbott Laboratories said on Saturday that it has reopened its baby formula production plant in Sturgis, Michigan, taking a step toward alleviating an acute nationwide shortage that has sent parents scrambling for supplies.

Investors Business Daily

Abbott Stock Looks To Emerge From Bear Market Stronger

A Relative Strength Rating upgrade for Abbott stock shows improving technical performance. Will it continue?

The Guardian - AU

Australian company to ship baby formula to shortage-hit US

Joe Biden welcomes ‘good news’ as Bubs Australia increases production and reassures local customers

Benzinga

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.65% on an annualized basis producing an average annual return of 14.68%. Currently, Abbott Laboratories has a market capitalization of $203.74 billion.

1 … 3 4 5 6

People

Joe Biden

66,185 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

US Food and Drug Administration

64 stories

Edwards Lifesciences

61 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.